Status:
COMPLETED
Patupilone Activity in Advanced/Metastatic Hepatocellular Carcinoma
Lead Sponsor:
Novartis Pharmaceuticals
Conditions:
Hepatocellular Carcinoma
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
This study will evaluate the safety, efficacy, and activity of patupilone in patients with advanced unresectable and/or metastatic hepatocellular carcinoma based on tumor response using modified RECIS...
Eligibility Criteria
Inclusion
- Inclusion criteria:
- \- Hepatocellular carcinoma patients with at least 1 previously un-irradiated, measurable lesion without any systemic single agent or combination chemotherapy. Previous local therapy is allowed.
- Exclusion criteria:
- Additional protocol-defined inclusion/exclusion criteria apply.
Exclusion
Key Trial Info
Start Date :
January 1 2006
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
Estimated Enrollment :
25 Patients enrolled
Trial Details
Trial ID
NCT00273312
Start Date
January 1 2006
Last Update
February 7 2017
Active Locations (7)
Enter a location and click search to find clinical trials sorted by distance.
1
Novartis Investigative Site
San Francisco, California, United States, 94115
2
Novartis Investigative Site
Hong Kong, Shatin, NT, Hong Kong
3
Novartis Investigative Site
Hong Kong, Hong Kong
4
Novartis Investigative Site
Seoul, Korea, South Korea, 110 744